AKTX Akari Therapeutics, Plc: רווח נקי למניה ב-12 החודשים האחרונים

The history of EPS YoY (ttm) percentage changes demonstrates the profit dynamics of Akari Therapeutics (AKTX), where the indicator value reaches 0.00. Akari Therapeutics (AKTX) develops high-precision solutions for the therapy of rare immune pathologies by targeting blood proteins. The strategy is based on complement regulation to protect patent rights, while the operating model relies on delegating final trials to external contractors under strict supervision.
Akari Therapeutics, Plc - פילוחים אנליטיים ומדדי מפתח (AKTX)

Investors are assessing the resilience of Akari Therapeutics (AKTX) through the dynamics of earnings per share over the last 12 months relative to the previous year. The current EPS YoY TTM growth rate reflects the monetization efficiency of unique orphan disease treatments and the progress of R&D stages under FDA supervision. This indicator determines whether a monopoly position within a clinical niche is being transformed into actual financial results.